Antisoma awarded US Qualifying Therapeutic Discovery Project grant of USD 244K
(Thomson Reuters ONE) -
London, UK, and Cambridge, MA: 8 November 2010 - Cancer drug developer Antisoma
plc (LSE: ASM; USOTC: ATSMY) today announces that the Company's US subsidiary,
Antisoma, Inc., has received a grant of USD 244,000 under the U.S. Government's
Qualifying Therapeutic Discovery Project, a programme created as part of the
Patient Protection and Affordable Care Act of 2010. The grant is to support the
ongoing development of AS1413 (amonafide L-malate), Antisoma's novel treatment
for acute myeloid leukaemia (AML).
Qualifying Therapeutic Discovery Project grants are awarded to projects that
show a reasonable potential to result in new therapies to treat areas of unmet
medical need or prevent, detect or treat chronic or acute diseases and
conditions, reduce the long-term growth of health care costs in the United
States, or significantly advance the goal of curing cancer within 30 years.
Dr Chris Smyth, VP, Clinical Operations at Antisoma, Inc., said: "We are pleased
that the development of AS1413 has qualified for this recognition, and look
forward to reporting the key phase III data on the drug in the near future."
Enquiries:
Antisoma plc +44 (0)7909 915 068
Glyn Edwards, Chief Executive Officer
Daniel Elger, VP, Marketing & Communications
Buchanan Communications +44 (0)20 7466 5000
Mark Court, Jessica Fontaine
Except for the historical information presented, certain matters discussed in
this statement are forward looking statements that are subject to a number of
risks and uncertainties that could cause actual results to differ materially
from results, performance or achievements expressed or implied by such
statements. These risks and uncertainties may be associated with product
discovery and development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and regulatory
filings. Such statements are based on management's current expectations, but
actual results may differ materially.
Background on Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company that
develops novel products for the treatment of cancer. The Company has operations
in London, UK and Cambridge, MA. Please visitwww.antisoma.com for further
information about Antisoma.
[HUG#1460039]
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Antisoma plc via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 08.11.2010 - 14:00 Uhr
Sprache: Deutsch
News-ID 48524
Anzahl Zeichen: 3202
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 184 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Antisoma awarded US Qualifying Therapeutic Discovery Project grant of USD 244K"
steht unter der journalistisch-redaktionellen Verantwortung von
Antisoma plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
